{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-010454","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.501024+00:00","generated_at":"2026-05-31T09:53:24.495517+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tenax Therapeutics reports Q2 net loss of $3.6M, cash $9.4M; raised $100M","bullets":["Net loss of $3.6M ($1.83/sh) vs loss of $1.1M ($4.00/sh) in Q2 2023.","R&D expenses $2.3M, up from $0.2M due to Phase 3 LEVEL study costs.","Cash and equivalents $9.4M at June 30; subsequent private placement raised $100M gross.","Phase 3 LEVEL study enrolling with 39 investigative sites; patent granted for levosimendan in PH-HFpEF.","G&A expenses $1.3M vs $1.0M in prior-year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-010454","json":"https://secwatch.observer/filing/0001654954-24-010454.json","markdown":"https://secwatch.observer/filing/0001654954-24-010454.md","text":"https://secwatch.observer/filing/0001654954-24-010454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010454/0001654954-24-010454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010454/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:53:24.495517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}